| 摘要 |
<p>The present invention provides a novel multianalyte LabMAPTM profiling technology that allows simultaneous measurement of multiple markers. In particular, a method is provided for diagnosing the presence of pancreatic cancer in a patient by measuring serum levels of markers in a blood marker panel comprising at least IP-10, HGF, IL-8, ?FGF, IL-12p40, TNFRI, TNFRII, Eotaxin, MCP-1 and CA 19-9, wherein a significant increase in the serum concentrations of IP-10, HGF, IL-8, ?FGF, IL-12p40, TNFRI, TNFRII, and CA 19-9 compared to healthy matched controls, and a significant decrease in the serum levels of Eotaxin and MCP-1 compared to healthy matched controls, indicates a probable diagnosis of pancreatic cancer in the patient. Also provided is a method to distinguish pancreatic cancer from chronic pancreatitis by measuring serum levels of markers in a blood marker panel. The present invention further provides a method of predicting the onset of clinical pancreatic cancer in a patient by determining the change in concentration at two or more time points of serum levels of markers on a blood marker panel.</p> |
